Codex DNA
General Information | |
Business: | We believe that we are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Our synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. |
Industry: | LABORATORY ANALYTICAL INSTRUMENTS |
Employees: | 96 |
Founded: | 2011 |
Contact Information | |
Address | 9535 Waples Street, Suite 100, San Diego, CA 92121-2993 |
Phone Number | (858) 228-4115 |
Web Address | http://www.codexdna.com/ |
View Prospectus: | Codex DNA |
Financial Information | |
Market Cap | $423.45mil |
Revenues | $7.9 mil (last 12 months) |
Net Income | $-21.6 mil (last 12 months) |
IPO Profile | |
Symbol | DNAY |
Exchange | NASDAQ |
Shares (millions): | 6.7 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $106.7 mil |
Manager / Joint Managers | Jefferies/ Cowen and Company/ KeyBanc Capital Markets |
CO-Managers | - |
Expected To Trade: | 6/18/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |